Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in heart failure with preserved ejection fraction
2023-506207-26-00Phase 3Authorised
- Sponsor
- Gentofte Hospital
- Start
- Sep 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of colchicine and Placebo-COD Research Private Ltd in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Gentofte Hospital. Primary endpoint: Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. Planned start Sep 2023; status: authorised.
02
Drugs
colchicinePlacebo-COD Research Private Ltd
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2023-506207-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506207-26-00.